UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 10-Q

 

FORM 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 


(Mark One)

[ X ]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 20152022

 

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

[   ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _____________to ________________________ to ___________

 

Commission file number 333-193599000-56035

 

TEXAS JACK OIL & GASGLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of small business issuerregistrant as specified in its charter)

 

Nevada

Nevada

46-2316220

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

1130 Calle Cordillera
San Clemente, California92673
(Address of principal executive offices)(Zip Code)

 

A-2-1, Block A, South Gate Commercial Centre(714) 392-9752

Jalan 2, Off Jalan Chan Sow Lin

55200 Kuala Lumpur, West Malaysia

(Address of principal executive offices)

+603-9226 0266

(Issuer’sRegistrant’s telephone number)number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the pastpreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]   x No [   ]  

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T



1




232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X]   x No [   ]  


  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See definitionthe definitions of “large accelerated filer”,filer,” “accelerated filer”filer,” “smaller reporting company,” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filerAccelerated filer ☐

Larger accelerated filer [   ]   

Accelerated filer [   ]   

Non-accelerated filer [   ]   

Smaller reporting company [X ]   

Emerging growth company

1

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [   ] No [ X ]  


x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 26,172,000107,587,079 shares of common stock, par value $0.001, were outstanding as of May 17, 2015



TEXAS JACK OIL & GAS CORPORATION

TABLE OF CONTENTS

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements

Condensed Balance Sheets as of March 31, 2015 (Unaudited) and June 30, 2014

Condensed Statements of Operations for the three and nine months ended March 31, 2015 and 2014 (Unaudited)

Condensed Statements of Cash Flows for the Nine Months Ended March 31, 2015 and 2014 (Unaudited)

Notes to Condensed Financial Statements (Unaudited)

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 4.

Controls and Procedures

PART II.

OTHER INFORMATION

Item 1.

Legal Proceedings

Item 2.

Recent Sales of Unregistered Securities and Use of Proceeds

Item 3.

Defaults Upon Senior Securities

Item 4.

Mine Safety Disclosures

Item 5.

Other Information

Item 6.

Exhibits

Signatures


on July 20, 2022.

 

 

 



3




2

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

FORM 10-Q

For the Quarterly Period Ended March 31, 2022

3

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements


TEXAS JACK OIL & GASGLOBAL WHOLEHEALTH PARTNERS CORPORATION

CONDENSEDCONSOLIDATED BALANCE SHEETS

 

 

March 31,

 

 

June 30,

 

 

 

2015

 

 

2014

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$

15

 

 

$

5,874

 

Total Current Assets

 

 

15

 

 

 

5,874

 

 

 

 

 

 

 

 

 

 

Loan receivable - officer

 

 

12,466

 

 

 

53,880

 

Right on mine property

 

 

165,000

 

 

 

165,000

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

177,481

 

 

$

224,754

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Notes payable

 

$

0

 

 

$

72,000

 

Note payable - related party

 

 

0

 

 

 

-

 

Accounts payable and accrued expenses

 

 

48,238

 

 

 

36,384

 

Accrued interest - related party

 

 

9,666

 

 

 

6,833

 

Total current liabilities

 

 

57,904

 

 

 

115,217

 

Non-Current liabilities

 

 

 

 

 

 

 

 

Note payable - related party

 

 

-

 

 

 

71,000

 

Total non-current liabilities

 

 

-

 

 

 

71,000

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

57,904

 

 

 

186,217

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Stockholders' (deficit) equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000,000 shares authorized

 

 

-

 

 

 

-

 

Common stock, $0.001 par value, 60,000,000 shares authorized, 26,172,000 and 23,400,000 shares issued and outstanding as of March 31, 2014 and June 30, 2014, respectively

 

 

26,172

 

 

 

23,400

 

Additional paid in capital

 

 

404,628

 

 

 

150,000

 

Accumulated deficit

 

 

(311,223

)

 

 

(134,863

)

Total stockholders' (deficit) equity

 

 

119,577

 

 

 

38,537

 

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' (deficit) equity

 

$

177,481

 

 

$

224,754

 

  March 31, June 30,
  2022 2021
ASSETS (Unaudited)  
Current assets:        
Cash $27,416  $74,702 
Prepaid expenses and other current assets  111,226   27,918 
Inventory, net  86,000   29,681 
Deferred financing costs  —     271,814 
Total current assets  224,642   404,115 
         
Operating lease right-of-use asset  476,125   —   
Equipment, net of accumulated depreciation of $1,939 and $1,067  1,565   2,438 
Investment in related party common stock  5,000   5,000 
Deposits  32,621   —   
Total assets $739,953  $411,553 
         
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)        
         
Current liabilities:        
Related party note $—    $2,785 
Convertible notes payable, net of discount of $0 and $27,460, respectively  806,400   85,000 
Notes payable  —     43,320 
Accounts payable and accrued liabilities  362,357   148,946 
Related party payables  638,827   225,598 
Lease liabilities, current  88,348   —   
Total current liabilities  1,895,932   508,649 
Lease liabilities, non-current  391,375     
Total liabilities  2,287,307   508,649 
         
Commitments and contingencies        
         
Stockholders' equity (deficit):        
Common stock; $0.001 par value, 400,000,000 shares authorized, 107,587,079 and 78,713,899 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively  107,486   78,714 
Additional paid-in capital  17,136,506   13,529,861 
Common stock payable  8,700   77,061 
Deferred compensation  (32,250)  —   
Retained deficit  (18,767,796)  (13,782,732)
Total stockholders' equity (deficit)  (1,547,354)  (97,096)
Total liabilities and stockholders' equity (deficit) $739,953  $411,553 
         
(The accompanying notes are an integral part of these consolidated financial statements)
         
4

GLOBAL WHOLEHEALTH PARTNERS CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)  
                 
   

Three Months Ended

March 31,

   

Nine Months Ended

March 31,

 
   2022   2021   2022   2021 
Revenue $7,000  $2,460  $7,375  $39,920 
Cost of revenue  33,681   54,540   33,681   82,671 
Gross profit  (26,681)  (52,080)  (26,306)  (42,751)
                 
Operating expenses                
Professional fees  32,132   14,400   103,532   61,625 
Research and development - related party  —     20,000   1,369,097   213,310 
Research and development  3,000   10,000   3,600   20,700 
Selling, general and administrative - related party  659,250   2,544,000   773,750   2,582,381 
Selling, general and administrative  212,260   22,980   1,741,622   39,260 
Total operating expense  906,642   2,611,380   3,991,601   2,917,276 
Loss from operations  (933,323)  (2,663,460)  (4,017,907)  (2,960,027)
Other income (expense)                
Interest expense  (690)  (760,553)  (279,697)  (796,427)
Amortization of debt discount  —     (57,604)  (687,460)  (157,980)
Loss on related party transfer of intangible assets  —     (4,480,000)  —     (4,480,000)
Total other income (expense)  (690)  (5,298,157)  (967,157)  (5,434,407)
Net loss $(934,013) $(7,961,617) $(4,985,064) $(8,394,434)
                 
Basic and Diluted Loss per Common Share $(0.01) $(0.12) $(0.06) $(0.14)
                 
Weighted average number of common shares outstanding - basic and diluted  93,988,841   65,856,044   87,439,163   62,047,517 
                 
                 
(The accompanying notes are an integral part of these consolidated financial statements)
                 
5

GLOBAL WHOLEHEALTH PARTNERS CORPORATION    
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)  
FOR THE NINE MONTHS ENDED MARCH 31, 2022      
    Common Stock   Additional Paid-in Capital   Common Stock Payable   Deferred Compensation   Retained Deficit   Total Stockholders' Equity (Deficit) 
  Shares   Amount                     
BALANCE JULY 1, 2021  78,713,899  $78,714  $13,529,861  $77,061  $—    $(13,782,732) $(97,096)
Common stock sold pursuant to the EMC2 SPA  3,438,484   3,438   799,748   —     —     —     803,186 
Common stock issued upon conversion of convertible promissory note  250,000   250   76,811   (77,061)  —     —     —   
Common issued stock related to services  750,000   750   354,000   129,000   (96,750)  —     387,000 
Discount on convertible promissory notes due to beneficial conversion feature  —     —     538,200   —     —     —     538,200 
   Net loss for the three months ended September 30, 2021  —     —     —     —     —     (1,433,221)  (1,433,221)
Balance, September 30, 2021  83,152,383   83,152   15,298,620   129,000   (96,750)  (15,215,953)  198,069 
Common stock sold pursuant to the EMC2 SPA  2,082,287   2,082   322,918   —     —     —     325,000 
Common stock issued for to services  2,750,000   2,750   687,600   (129,000)  32,250   —     593,600 
   Net loss for the three months ended December 31, 2021  —     —     —     —     —     (2,617,830)  (2,617,830)
Balance, December 31, 2021  87,984,670   87,984   16,309,138   —     (64,500)  (17,833,783)  (1,501,161)
Common stock sold pursuant to the EMC2 SPA  2,335,743   2,335   74,535   —     —     —     76,870 
Common stock issued for services  12,500,000   12,500   675,500   8,700   32,250   —     728,950 
Common stock issued upon exercise of warrant  2,000,000   2,000   —     —     —     —     2,000 
Common stock upon conversion of convertible promissory note principal  2,666,666   2,667   77,833   —     —     —     80,000 
   Net loss for the three months ended March 31, 2022  —     —     —     —     —     (934,013)  (934,013)
Balance, March 31, 2022  107,487,079  $107,486  $17,136,506  $8,700  $(32,250) $(18,767,796) $(1,547,354)
                             

6

               
               
FOR THE NINE MONTHS ENDED MARCH 31, 2021           
BALANCE JULY 1, 2020  59,966,358  $59,966  $4,628,908  $—    $—    $(4,748,609) $(59,735)
Common stock issued for cash  —     —     —     340,000   —     —     340,000 
Discount on convertible promissory notes due to beneficial conversion feature  —     —     123,831   —     —     —     123,831 
   Net loss for the three months ended September 30, 2020  —     —     —     —     —     (247,163)  (247,163)
Balance, September 30, 2020  59,966,358   59,966   4,752,739   340,000   —     (4,995,772)  156,933 
Common stock issued for cash  —     —     —     90,000   —     —     90,000 
   Net loss for the three months ended December 31, 2020  —     —     —     —     —     (185,654)  (185,654)
Balance, December 31, 2020  59,966,358   59,966   4,752,739   430,000   —     (5,181,426)  61,279 
Common stock issued for cash  514,298   514   429,486   (430,000)  —     —     —   
Common stock issued upon conversion of convertible promissory note  146,486   147   55,503   —     —     —     55,650 
Common stock issued for services  2,950,000   2,950   2,541,050   —     —     —     2,544,000 
Common stock issued for license agreements with Charles Strongo  8,000,000   8,000   4,472,000   —     —     —     4,480,000 
Common stock issued as compensation for financings  1,415,094   1,415   1,258,019   —     —     —     1,259,434 
Net loss for the three months ended March 31, 2021  —     —     —     —     —     (7,961,617)  (7,961,617)
Balance, March 31, 2021  72,992,236  $72,992  $13,508,797  $—    $—    $(13,143,043) $438,746 
                             
                             
(The accompanying notes are an integral part of these consolidated financial statements)

7

GLOBAL WHOLEHEALTH PARTNERS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
   Nine Months Ended March 31,
   2022   2021 
Cash flows from operating activities        
Net loss $(4,985,064) $(8,394,434)
Adjustments to reconcile net loss to net cash flows used in operating activities:        
Loss on related party transfer of intangible assets  —     4,480,000 
Common stock issued for services  1,709,550   7,256,600 
Amortization of debt discount  687,460   157,980 
Penalties on default of Firstfire Notes  191,400   —   
Non cash lease expense  3,598   —   
Depreciation and amortization  873   776 
Changes in operating assets and liabilities:        
(Increase) decrease in accounts receivable  —     (651)
(Increase) decrease in prepaid expenses and other assets  (115,929)  (15,069)
(Increase) decrease in inventory  (56,319)  (2,911)
Increase (decrease) in accounts payable and accrued expenses  213,411   (3,960)
Increase (decrease) related party payables  410,229   (161)
Net cash flows used in operating activities  (1,940,791)  (496,861)
         
Cash flows used in investing activity        
Purchase of equipment  —     (3,505)
Net cash flows used in investing activity  —     (3,505)
         
Cash flows from financing activities        
Proceeds from sale of common stock  1,478,870   430,000 
Proceeds from convertible promissory notes  538,200   162,000 
Payments of convertible promissory notes  (50,000)  (73,000)
Payments of promissory notes  (70,780)  —   
Proceeds from related party note, net  —     105,198 
Payments of related party note  (2,785)  (137,500)
Net cash flows from  financing activities  1,893,505   486,698 
Change in cash  (47,286)  (13,668)
Cash at beginning of period  74,702   14,497 
Cash at end of period $27,416  $829 
         
Supplemental disclosure of cash flow information:        
Interest paid in cash $11,875  $—   
Income taxes paid in cash $—    $—   
         
Supplemental disclosure of non-cash transactions:        
Common stock issued for conversion of note payable $80,000     
Debt discount recorded for beneficial conversion feature $356,656  $—   
         
(The accompanying notes are an integral part of these consolidated financial statements)
8

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2022 AND 2021

NOTE 1 –Organization and Going Concern

Organization

Global WholeHealth Partners Corporation was incorporated on March 7, 2013 in the State of Nevada under the name Texas Jack Oil and Gas Corp. On May 9, 2019, the Company amended its Articles of Incorporation to effect a change of name to Global WholeHealth Partners Corporation. The Company’s ticker symbol changed to GWHP.

The Company develops in-vitro diagnostic products, including rapid diagnostic tests, such as the COVID-19 Test, 6-minute rapid whole blood Ebola Test, 6-minute whole blood Zika test, 8-minute whole blood rapid TB test and over 75 other tests.

Going Concern

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as a going concern.
As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $1,940,791 for the nine months ended March 31, 2022 and has an accumulated deficit of $18,767,796 from inception through March 31, 2022. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

In view of these conditions, the ability of the Company to continue as a going concern is in doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. Historically, the Company has relied upon internally generated funds, and funds from the sale of stock, issuance of promissory notes and loans from its shareholders and private investors to finance its operations and growth. Management is planning to raise necessary additional funds for working capital through loans and/or additional sales of its common stock. However, there is no assurance that the Company will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should the Company be unable to raise this amount of capital its operating plans will be limited to the amount of capital that it can access. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

NOTE 2 – Interim Statement Presentation

Basis of Presentation

 

The accompanying notes are an integral part of these unaudited condensed financial statements







TEXAS JACK OIL & GAS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

For the Three

 

 

For the Three

 

 

For the Nine

 

 

For the Nine

 

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

 

Months Ended

 

 

 

March 31

 

 

March 31

 

 

March 31

 

 

March 31

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

-

 

 

$

386

 

 

$

-

 

 

$

4,083

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

1,770

 

 

 

5,331

 

 

 

171,115

 

 

 

39,629

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

1,770

 

 

 

5,331

 

 

 

171,115

 

 

 

39,629

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Operating Loss

 

 

(1,770

)

 

 

(4,945

)

 

 

(171,115

)

 

 

(35,546

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

0

 

 

 

1,993

 

 

 

5,045

 

 

 

6,039

 

Total other expenses

 

 

0

 

 

 

1,993

 

 

 

5,045

 

 

 

6,039

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before provision for income taxes

 

 

(1,770

)

 

 

(6,938

)

 

 

(176,160

)

 

 

(41,585

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,770

)

 

$

(6,938

)

 

$

(176,160

)

 

$

(41,585

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - basic

 

$

(0.00

)

 

$

(0.00

)

 

$

(0.01

)

 

$

(0.00

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - diluted

 

$

(0.00

)

 

$

(0.00

)

 

$

(0.01

)

 

$

(0.00

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

 

25,408,739

 

 

 

23,324,444

 

 

 

25,152,087

 

 

 

23,106,569

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - diluted

 

 

25,408,739

 

 

 

23,324,444

 

 

 

25,152,087

 

 

 

23,106,569

 

The accompanying notes are an integral part of these unaudited condensed financial statements




TEXAS JACK OIL & GAS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

For the Nine

 

 

For the Nine

 

 

 

Months Ended

 

 

Months Ended

 

 

 

March 31,

 

 

March 31,

 

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(176,160

)

 

$

(41,585

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Loan receivable - officer

 

 

41,414

 

 

 

(3,195

)

Accrued interest - related party

 

 

2,833

 

 

 

4,234

 

Accounts payable and accrued expenses

 

 

11,854

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

(120,059

)

 

 

(40,546

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Proceeds from issuance of private placement

 

 

119,200

 

 

 

400

 

Payments to officer under note receivable

 

 

-

 

 

 

(10,700

)

Repayments from officer under note receivable

 

 

-

 

 

 

4,050

 

Proceed from issuance of promissory notes

 

 

-

 

 

 

5,000

 

Repayments of promissory notes

 

 

(5,000

)

 

 

-

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) financing activities

 

 

114,200

 

 

 

(1,250

)

 

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

 

(5,859

)

 

 

(41,796

)

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

 

5,874

 

 

 

42,681

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$

15

 

 

$

885

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Interest paid

 

$

-

 

 

$

-

 

Income taxes paid

 

$

-

 

 

$

-

 















TEXAS JACK OIL & GAS CORPORATION

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2015


NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES


A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensedinterim consolidated financial statements follows:


General


The interim condensed consolidated financial statements included hereinof Global Wholehealth Partners Corporation and its controlled subsidiary, Global WholeHealth Partners Corp, a private Wyoming corporation (collectively, the “Company”), as of March 31, 2022, and for the three and nine months ended March 31, 2022 and 2021 have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”SEC) as promulgated in Item 210for quarterly reports on Form 10-Q and do not include all of Regulation S-X. Certainthe information and footnotenote disclosures normally included in financial statements prepared in accordance withrequired by U.S. generally accepted accounting principles generally accepted in the United States of America (“US GAAP”U.S. GAAP) have been condensed or omitted pursuant to such SEC rules and regulations.


In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three and nine month periods ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ending June 30, 2015. The unauditedcomplete financial statementsstatements. These Consolidated Financial Statements should therefore be read in conjunction with the financial statementsConsolidated Financial Statements and footnotesNotes thereto for the fiscal year ended June 30, 2014,2021 included in the Company’sour Annual Report on Form 10-K filed with the SEC on September 30, 2014.27, 2021.


9

Business and Basis of Presentation


Texas Jack Oil & Gas Corporation (the “Company”), was incorporated on March 7, 2013 under the laws of the State of Nevada. The Company is headquartered in California and was organized for the purpose of exploration of Oil and Gas.


As the Company is devoting substantially all of its efforts to establishing a new business, and planned principal operations have not yet commenced. To date, the Company, has not generated sales revenues, has incurred expenses and has sustained losses since inception and expects these conditions to continue for the foreseeable future. Consequently, its operations are subject to all the risks inherent in the establishment of a new business enterprise.


The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying unaudited condensedinterim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared assumingon the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the Company will continueopinion of management, necessary for a fair presentation of the Company’s consolidated financial position as a going concernof March 31, 2022, results of operations, stockholders’ equity and do not include any adjustments that may result fromcash flows for the outcome of this uncertainty.


Revenue Recognition


three and nine months ended March 31, 2022 and 2022. The Company will recognize revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidencedid not record an income tax provision during the periods presented due to net taxable losses. The results of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4)operations for any interim period are based on management's judgments regarding the fixed naturenot necessarily indicative of the selling pricesresults of operations for the products delivered and the collectability of those amounts.entire year.

 

The Company will account for Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Estimates




7




The preparation of unaudited condensedconsolidated financial statements in accordanceconformity with accounting principlesU.S. generally accepted in the United Statesaccounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the accounting period. The Company considers its accounting policies relating to convertible debt to be the most significant accounting policy that involves management estimates and judgments. The Company has made accounting estimates based on the facts and circumstances available as of the reporting period.date. Actual resultsamounts could differ from those estimates.these estimates, and such differences could be material.

 

Information regarding the Company’s significant accounting policies is contained in Note 2, “Summary of significant accounting policies,” to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021. Presented below and in the following notes is supplemental information that should be read in conjunction with “Notes to Financial Statements” in the Annual Report.

Accounting Pronouncements

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

New Accounting Pronouncements Not Yet Adopted

None.

Accounting Pronouncements Recently Adopted

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for the Company for fiscal years beginning after December 31, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the beginning of the Company’s annual fiscal year. The Company adopted ASU 2020-06 beginning with our fiscal year starting on July 1, 2021 with no impact on its Financial Statements. 

In January 2020, the FASB issued ASU 2020-01 - Investments - Equity securities (Topic 321), Investments - Equity method and joint ventures (Topic 323), and Derivatives and hedging (Topic 815) - Clarifying the interactions between Topic 321, Topic 323, and Topic 815. The amendments in this Update improve the accounting for certain equity securities upon the application or discontinuation of the equity method of accounting and clarify the scope considerations for forward contracts and purchased options on certain securities. The amendments are effective for public entities in fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2020-01 beginning with our fiscal year starting on July 1, 2021 with no impact on its Financial Statements.

10

In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes. The guidance removes certain exceptions for recognizing deferred taxes for equity method investments, performing intra period allocation, and calculating income taxes in interim periods. The ASU also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for goodwill and allocating taxes to members of a consolidated group, among others. This guidance is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The transition requirements are dependent upon each amendment within this update and will be applied either prospectively or retrospectively. The Company adopted ASU 2019-12 effective July 1, 2021 with no impact on its Financial Statements.

NOTE 3 - Net Income (Loss) perPer Share


The Company computescomputation of basic earnings per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share(“ASC 260-10”EPS). Net earnings (losses) per common share is computed by dividing net income (loss) bybased on the weighted average number of shares that were outstanding during the period, including shares of common stock and dilutivethat are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common stock equivalents outstanding during the period. Dilutive common stock equivalents consisted of shares issuable uponthat would be issued assuming the exercise of the Company'sall potentially dilutive common shares outstanding warrants (calculated using the treasury stock method)method. The computation of diluted net income per share does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on earnings per share. Therefore, when calculating EPS if the Company experienced a loss, there is no inclusion of dilutive securities as their inclusion in the EPS calculation is antidilutive. Furthermore, options and warrants will have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options or warrants (they are in the money).

Following is the computation of basic and diluted net loss per share for the three and nine months ended March 31, 2015; there were no common stock equivalents for the three2022 and nine months ended March 31, 2015.


Reliance on Key Personnel and Consultants


The Company has no full-time employees and no part-time employees. There are approximately 2 consultants performing various specialized services. The Company is heavily dependent on the continued active participation of these current executive officers, and key consultants. The loss of any of the senior management or key consultants could significantly and negatively impact the business until adequate replacements can be identified and put in place.


Recent Accounting Pronouncements


There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.2021:

 

NOTE 2 – GOING CONCERN MATTERS

The accompanying unaudited condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during the nine months ended March 31, 2015, the Company incurred net losses attributable to common stockholders of $176,160. In addition, the Company has yet commercialized its planned business and has generated very little revenues since inception. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company's existence is dependent upon management's ability to develop profitable operations. Additional capital will be needed to continue developing its products and services and there can be no assurance that the Company's efforts will be successful. There is no assurance that can be given that management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying unaudited condensed financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.


NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

As of March 31, 2015 and June 30, 2014 accounts payable and accrued liabilities consisted of the following:

 

 

March 31,

 

 

June 30,

 

 

 

2015

 

 

2014

 

Accounts Payable

 

$

16,042

 

 

$

-

 

Accrued Expenses - Consulting

 

 

27,358

 

 

 

33,758

 

Accrued Interest

 

 

4,838

 

 

 

2,626

 

Accounts Payable and Accrued Liabilities

 

$

48,238

 

 

$

36,384

 





NOTE 4 – RELATED PARTY TRANSACTIONS

The Company’s former officer and shareholder has borrowed $102,200, net of repayments of $5,720 since the Company’s inception in March 2013. These are interest free advances.  During the nine months ended March 31, 2015 the Company reclassified $83,980 of this receivable as officer compensation. As of March 31, 2015 the Company has receivables in the amount of $12,466 due from the officer and shareholder.

In March 2013, the Company issued 15,000,000 of shares to the founder of the Company, for purchase of an interest in a mine property valued at $165,000, which was the original cost to the founder. The mine interest was assigned to the Company on May 1, 2013 through a partial assignment agreement. The Company also presently owns a 3% percent working lease interest in one well located in Jack County, Texas.

NOTE 5 – PROMISSORY NOTE - SHAREHOLDER

On April 15, 2013, the Company received $71,000 on issuance of 8% unsecured promissory note from a shareholder, which was originally due on April 15, 2014; in May 2014 this note was extended to October 1, 2015.  Total interest expense for the six months ended March 31, 2014 and 2013 on the above note was $2,833 and $2,833, respectively; and for the three months ended March 31, 2014 and 2013 was $1,432 and $1,432, respectively.  Total accrued interest as of March 31, 2014 and June 30, 2014 is $9,666 and $6,833, respectively.  The default rate of interest is 1.5% per month. On February 6, 2015 the lender agreed to convert the principal balance of the note into 710,000 shares of the Company’s common stock.  The note holder agreed to forgo any interest payments due.

NOTE 6 – PROMISSORY NOTE

On June 7, 2013, the Company received $40,000 on issuance of 5% unsecured promissory note, which was originally due on November 30, 2013.  The maturity date was extended to June 1, 2014 and subsequently extended to March 31, 2014.  During the six months ended March 31, 2014 the company repaid $5,000 in principal on this note.  As of March 31, 2014 the balance on this note was $35,000.  During the six months ended March 31, 2014 and 2013, the Company recorded interest expense of $922 and $1,112, respectively; and during the three months ended March 31, 2014 and 2013, recorded interest expense of $441 and $504, respectively, on this note.  Total accrued interest as of March 31, 2014 and June 30, 2014 is $3,026 and $2,104, respectively.  The note was not repaid at maturity.  On February 6, 2015 the lender agreed to convert the principal balance of the note into 350,000 shares of the Company’s common stock.  The note holder agreed to forgo any interest payments due.

On September 5, 2013, the Company received $5,000 on issuance of an 8% unsecured promissory note, which was originally due on September 5, 2014. The maturity date was extended to December 5, 2014.  Default rate of interest is 1.5% per month. During six months ended March 31, 2014 and 2013, the Company recorded interest expense of $202 and $101, respectively; and during the three months ended March 31, 2014 and 2013, recorded interest expense of $101 and $101, respectively, on this note.  Total accrued interest as of March 31, 2014 and June 30, 2014 is $502 and $300, respectively.  The note was not repaid at maturity.  On February 6, 2015 the lender agreed to convert the principal balance of the note into 50,000 shares of the Company’s common stock.  The note holder agreed to forgo any interest payments due.


On May 22, 2014, the Company received $25,000 on issuance of an 8% unsecured promissory note, which is due on May 22 2015.  Default rate of interest is 1.5% per month.  During six months ended March 31, 2014 and 2013, the Company recorded interest expense of $1,008 and $0, respectively; and during the three months ended March 31, 2014 and 2013, recorded interest expense of $504 and $0, respectively, on this note.  Total accrued interest as of March 31, 2014 and June 30, 2014 is $1,222 and $214, respectively. On February 6, 2015 the lender agreed to convert the principal balance of the note into 250,000 shares of the Company’s common stock.  The note holder agreed to forgo any interest payments due.

On June 12, 2014, the Company received $2,000 on issuance of an 8% unsecured promissory note, which is due on June 12, 2015.  Default rate of interest is 1.5% per month.  During the six months ended March 31, 2014 and 2013,



9




the Company recorded interest expense of $80 and $0, respectively; and during the three months ended March 31, 2014 and 2013, recorded interest expense of $40 and $0, respectively, on this note.  Total accrued interest as of March 31, 2014 and June 30, 2014 is $88 and $8, respectively. On February 6, 2015 the lender agreed to convert the principal balance of the note into 20,000 shares of the Company’s common stock.  The note holder agreed to forgo any interest payments due.

On February 6, 2015 the Company agreed to convert the principal outstanding balance of five promissory notes into shares of common stock at a rate of $0.10 per share.  As part of the conversion the note holders agreed to forgo any interest payments due.  The Company issued 1,380,000 shares of common stock for the extinguishment of notes payable in the amount of $138,000.

  

Three Months Ended

March 31,

 

Nine Months Ended

March 31,

  2022 2021 2022 2021
Basic and diluted EPS Computation       
Numerator:       
 Loss available to common stockholders'$  (934,013) $ (7,961,617) $ (4,985,064) $  (8,394,434)
Denominator:       
 Weighted average number of common shares outstanding           93,988,841            65,856,044            87,439,163            62,047,517
Basic and diluted EPS Computation$        (0.01) $         (0.12) $         (0.06) $        (0.14)
         
The shares listed below were not included in the computation of diluted losses      
per share because to do so would be antidilutive for the periods presented:     
 Convertible notes39,202,647 10,221 39,202,647 10,221
 Warrants546,975 2,000,000 546,975 2,000,000
Total shares not included in the computation of diluted loss per share39,749,622 2,010,221 39,749,622 2,010,221


NOTE 3 – Stockholder’s Equity

 

NOTE 7 – STOCKHOLDERS EQUITY

Preferred stockStock

 

The Company has authorizedPreferred stock: $0.001 par value; 10,000,000 shares of preferred stock,authorized with a par value of $0.001 per share. As March 31, 2015 and June 30, 2014, the Company has no shares of preferred stock issued and outstanding.

 

Common stockStock

 

The Company has 400,000,000 shares of Common Stock authorized 60,000,000of which 107,587,079 and 78,713,899 shares were issued and outstanding as of March 31, 2022 and June 30, 2021, respectively.

11

On April 20, 2021, the Company and Empire Associates, Inc. entered into a Stock Purchase Agreement whereby the Company agreed to issue 250,000 to Empire Associates, Inc. in full satisfaction of the $77,060 paid to Geneva by Empire Associates on behalf of the Company. The shares were issued on September 2, 2021, and are included in the calculation of EPS on an as-if issued basis.

On July 10, 2021, the Company and LionsGate Funding Management LLC (“LGFM”) entered into a Media and Marketing Services Agreement (the “MMSA”). Pursuant to the MMSA, 1) LGFM will provide services designed to increase the awareness and visibility in the investment community and market product to distributors throughout the world for a period of 12 months; and 2) the Company will pay LGFM $100,000 and issue 300,000 shares of restricted common stock valued at $129,000. The shares were issued on October 11, 2021 and are included in the calculation of EPS on an as-if issued basis. Lionsgate was issued 2,500,000 shares on January 13, 2022 in exchange for services valued at $215,000.

On July 22, 2020, the Company entered into a Common Stock Purchase Agreement (the “EMC2 SPA”) and a Registration Rights Agreement with EMC2 Capital, LLC (“EMC2 Capital”) pursuant to which EMC2 Capital agreed to invest up to One Hundred Million Dollars ($100,000,000) to purchase the Company’s common stock at a purchase price as defined in the Common Stock Purchase Agreement (the "Purchase Shares"). During the three months ended March 31, 2022, the Company sold 2,335,743 Purchase Shares to EMC2 Capital at prices ranging from $0.02 - $0.06 and received total proceeds of $76,871. During the nine months ended March 31, 2022, the Company sold 7,856,514 Purchase Shares to EMC2 Capital at prices ranging from $0.02 - $0.34 and received total proceeds of $1,476,872.

During the three months ended March 31, 2022, the Company issued 12,500,000 shares in exchange for services valued at $688,000 inclusive of 9,000,000 shares issued to Board members valued at $387,000. During the nine months ended March 31, 2022, the Company issued 16,000,000 shares in exchange for services valued at $1,733,100.

During the three months ended March 31, 2022, EMC2 exercised their warrant to purchase 2,000,000 shares in exchange for the exercise price of $2,000.

During the three months ended March 31, 2022, Firstfire converted $80,000 or principal of Firstfire Note No. 1 at a per share price of $0.03, and received 2,666,666 shares of common stock.

Warrants

Each of the Company’s warrants outstanding entitles the holder to purchase one share of the Company’s common stock for each warrant share held. A summary of the Company’s warrants outstanding and exercisable as of March 31, 2022 and June 30, 2021 is as follows:

 Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average    
Description March 31, June 30, Exercise Price Date of Expiration
2022 2021Issuance 
EMC2 Capital - 2,000,000 variable July 22, 2020 July 22, 2025
Geneva 51,975 51,975 variable April 26, 2021 April 26, 2024
Firstfire Warrant 1 165,000 165,000 variable June 18, 2021 June 18, 2024
Firstfire Warrant 2 330,000 - variable August 27, 2021 August 27, 2024
Total 546,975 2,216,975      

NOTE 4 –Transactions with Related Persons

On July 10, 2021, the Company and LionsGate Funding Management LLC (“LGFM”) entered into a Media and Marketing Services Agreement (the “MMSA”). Pursuant to the MMSA, 1) LGFM will provide services designed to increase the awareness and visibility in the investment community and market product to distributors throughout the world for a period of 12 months. Pursuant to the MMSA, during the six months ended December 31, 2021, the Company paid LGFM $100,000 and issued 300,000 shares of restricted common stock.

12

Lionsgate was issued 2,500,000 shares on January 13, 2022 in exchange for services valued at $215,000.

On July 1, 2021, the Company paid LionsGate Funding Group LLC (“LionsGate”) $24,000 or $21,215 in excess of the balance owing to LionsGate which the Company recorded as a receivable. During the three and nine months ended March 31, 2022, LionsGate made payments on behalf of the company totaling $950 leaving a receivable balance of $20,265.

Beginning in January 2020, the Company utilizes the R&D capabilities of Pan Probe Biotech to perform studies and perform work towards development of the Company’s COVID-19 tests. Dr. Shujie Cui is the Company’s Chief Science Officer and 100% owner of Pan Probe. During the three months ended March 31, 2022, the Company incurred no R&D costs and made payments to Pan Probe totaling $15,000. During the nine months ended March 31, 2022, the Company incurred R&D costs of $1,369,097 and paid Pan Probe $1,015,000 for R&D work. During the six months ended March 31, 2021, the Company paid Pan Probe $190,000 for R&D work. As of March 31, 2022 and June 30, 2021 the balance due to Pan Probe was $582,577 and $228,480, respectively.

The Company paid rent to Pan Probe on a temporary basis, from April 21, 2020 through October 21, 2020, at a rate of $2,551 per month or $15,306 which was prepaid in full in April 2020. During the six months ended March 31, 2021, the Company recognized $10,204 of rent expense related to this arrangement.

Related Party Note

From time-to-time the Company receives shareholder advances from LionsGate to cover operating costs. On March 29, 2020, the Company issued a Promissory Note (the “Note”), and on June 30, 2020, amended the Note (the “Note Amendment”). Pursuant to the Note and Note Amendment, the terms provided for total funding of up to $585,000, interest at the rate of 5% per annum with the principal and interest due in-full on June 30, 2021. On January 27, 2021, the Company and LionsGate entered into a Loan Agreement (the “Loan Agreement”) and Promissory note (the “Promissory Note”) pursuant to which the Company may borrow up to $250,000 at an annual interest rate of 5% and default interest rate of 15%. The Loan Agreement supersedes the Note and Note Amendment and included a beginning balance of $29,951 which was the balance of advances and accrued interest owing under the Note as of January 27, 2021. The Promissory Note matured on December 31, 2021. During the three months ended March 31, 2022 2021, LionsGate provided advances totaling $0 and $66,776, respectively. During the six months ended March 31, 2022 and 2021, LionsGate provided advances totaling $0 and $106,698, respectively.

During the three and nine months ended March 31, 2022, the Company repaid LionsGate $0 and $24,000, respectively. During the three and nine months ended March 31, 2021, the Company repaid LionsGate $0 and $137,500, respectively. On July 1, 2021, under the Promissory Note, the Company mistakedly made an overpayment to LionsGate in the amount of $21,215 to which the Company applied $950 of advances leaving a receivable balance due from Lionsgate of $20,265 as of March 31, 2022.

During the three and nine months ended March 31, 2021, the Company recognized $584 and $1,212, respectively, of interest expense related to the Note.

NOTE 5 – Convertible Promissory Notes

On April 18, 2020, the Company issued five separate unsecured convertible promissory notes in exchange for $95,000 (the "Convertible Notes"). Each Convertible Note contains the same terms and conditions. The Convertible Notes bear interest of 8%, matured in six months on October 17, 2020 and are convertible at any time into shares of restricted common stock at a conversion price of $9.00 per share. The notes are currently in default. The debt discount attributable to the fair value of the beneficial conversion feature amounted to $42,224 for the Convertible Notes and was accreted over the term of the Convertible Notes. In December of 2020, the Company repaid, in-full, two of the Convertible Notes with principal a balance totaling $10,000 and $500 of interest payable. In November of 2021, the Company repaid, in-full, one of the Convertible Notes with principal a balance totaling $50,000 and $6,425 of interest payable. During the three months ended March 31, 2022 and 2021, the Company recognized $690 and $1,677, respectively, of interest expense; and $0 and $3,922, respectively, of accretion. During the nine months ended March 31, 2022 and 2021, the Company recognized $3,647 and $5,448, respectively, of interest expense; and $0 and $25,149, respectively, of accretion. As of March 31, 2022, the Convertible Notes principal balance is $35,000 and accrued interest balance is $4,716

13

Firstfire Global Opportunities Fund LLC

Firstfire Note No. 1

On June 18, 2021, the Company entered into a Securities Purchase Agreement with Firstfire Global Opportunities Fund LLC ("Firstfire"), for the sale of a secured, 12% senior secured convertible promissory note in the principle amount of $275,000 and 165,000 stock purchase warrants. On July 8, 2021, the Company received $224,500 net of a $25,000 original issue discount and $25,500 of placement agent and legal fees, and issued a senior secured convertible promissory note (the "Firstfire Note No. 1") in the amount of $275,000. The terms of the Firstfire Note No. 1 provide for all principal and interest due in twelve (12) months on June 18, 2022, with $33,000 of interest (i.e., $275,000 x 12%) earned as of June 18, 2021, interest due upon default of 20% annually, a prepayment penalty of 5% of all outstanding amounts due, and if the Company triggers and event of default which is not cured, then the total of all amounts owing will be increased by 25%, to be paid at the discretion of Firstfire, in the form of cash or conversion into common stock. The Firstfire Note No. 1 is convertible any time after June 18, 2021 into shares of common stock at a conversion price that is the lesser of $0.35 per share or seventy percent (70%) of the lowest traded price of our common stock during the ten (10) trading day period prior to conversion. Conversion of the Firstfire Note No. 1 and/or the Firstfire Warrant No. 1 is limited to Firstfire beneficially owning no more than 4.99% of the outstanding common stock of the Company.

Additionally, the Company entered into a Registration Rights Agreement with Firstfire whereby the Company agreed to file within 90 days and have declared effective within 120 days from June 18, 2021, a parregistration statement to cover the shares issuable under the Firstfire Note No. 1 and Firstfire Warrant No. 1. Failure to file within 90 days and have the registration declared effective before 120 days will result in liquidated damages of 1% principal amount.

Due to the Company not filing a registration statement to cover the shares underlying a Firstfire Note No. 1 conversion by the dates specified in the Registration Rights Agreement, the Firstfire Note No. 1 fell into default resulting in the Firstfire Note No. 1 becoming immediately due and the Company recognizing liquidated damages of $2,750 and $77,000 increase in the amount due.

As additional consideration, the Company granted Firstfire a warrant to purchase 165,000 shares of our common stock (the "Firstfire Warrant No. 1") at an exercise price of $0.50 for a period of three (3) years. The Firstfire Warrant No. 1 contains provision for an anti-dilution adjustment and cashless exercise rights if a registration statement covering the resale of the Firstfire Warrant No. 1 shares is not available for the resale of such Firstfire Warrant No. 1 shares. The fair value of $0.001the Firstfire Warrant No. 1 was $0.36 per share. share and was calculated using the Black-Scholes option pricing model with the following assumptions: (1) Stock price of $0.41 per share; (2) exercise price of $0.50 per share; (3) discount rate 0.47% (4) expected life of 3 years, (5) expected volatility of 194.5%, and (6) zero expected dividends. This resulted in allocating $48,849 to the Firstfire Warrant No. 1 and $226,151 to the Firstfire Note No. 1. Then, we calculated the debt discount attributable to the beneficial conversion feature which amounted to $264,372. As a result of the original issue discount, fees, warrant and beneficial conversion feature of the Firstfire Note No. 1, the Company recorded a debt discount of $275,000.

During the three months ended March 31, 2022, Firstfire converted $80,000 or principal of Firstfire Note No. 1 at a per share price of $0.03, and received 2,666,666 shares of common stock.

14

Firstfire Note No. 2

On August 27, 2021, the Company entered into a Securities Purchase Agreement with Firstfire, for the sale of a secured, 12% senior secured convertible promissory note in the principle amount of $385,000 and 330,000 stock purchase warrants. The Company received $313,700 net of a $35,000 original issue discount and $36,300 of placement agent and legal fees, and issued a senior secured convertible promissory note (the "Firstfire Note No. 2") in the amount of $385,000. The terms of the Firstfire Note No. 2 provide for all principal and interest due in twelve (12) months on August 27, 2022, with $46,200 of interest (i.e., $385,000 x 12%) earned as of August 27, 2021, interest due upon default of 20% annually, a prepayment penalty of 5% of all outstanding amounts due, and if the Company triggers and event of default which is not cured, then the total of all amounts owing will be increased by 25%, to be paid at the discretion of Firstfire, in the form of cash or conversion into common stock. The Firstfire Note No. 2 is convertible any time after August 27, 2021 if the underlying shares have an effective registration statement, otherwise, the right of conversion commences after 180 days from August 31, 2021 into shares of common stock at a conversion price that is the lesser of $0.35 per share or seventy percent (70%) of the lowest traded price of our common stock during the ten (10) trading day period prior to conversion. Conversion of the Firstfire Note No. 2 and/or the Firstfire Warrant No. 2 is limited to Firstfire beneficially owning no more than 4.99% of the outstanding common stock of the Company.

Additionally, the Company entered into a Registration Rights Agreement with Firstfire whereby the Company agreed to file within 90 days and have declared effective within 120 days from August 27, 2021, a registration statement to cover the shares issuable under the Firstfire Note No. 2 and Firstfire Warrant No. 2. Failure to file within 90 days and have the registration declared effective before 120 days will result in liquidated damages of 1% of the principal amount.

Due to the Company not filing a registration statement to cover the shares underlying a Firstfire Note No. 2 conversion by the dates specified in the Registration Rights Agreement, the Firstfire Note No. 2 fell into default resulting in the Firstfire Note No. 2 becoming immediately due and the Company recognizing liquidated damages of $3,850 and $107,800 increase in the amount due.

As additional consideration, the Company granted Firstfire a warrant to purchase 330,000 shares of our common stock (the "Firstfire Warrant No. 2") at an exercise price of $0.50 for a period of three (3) years. The Firstfire Warrant No. 2 contains provision for an anti-dilution adjustment and cashless exercise rights if a registration statement covering the resale of the Firstfire Warrant No. 2 shares is not available for the resale of such Firstfire Warrant No. 2 shares. The fair value of the Firstfire Warrant No. 2 was $0.32 per share and was calculated using the Black-Scholes option pricing model with the following assumptions: (1) Stock price of $0.37 per share; (2) exercise price of $0.50 per share; (3) discount rate 0.41% (4) expected life of 3 years, (5) expected volatility of 184.0%, and (6) zero expected dividends. This resulted in allocating $82,870 to the Firstfire Warrant No. 2 and $302,130 to the Firstfire Note No. 2. Then, we calculated the debt discount attributable to the beneficial conversion feature which amounted to $248,111. As a result of the original issue discount, fees, warrant and beneficial conversion feature of the Firstfire Note No. 2, the Company recorded a debt discount of $385,000.

During the three and nine months ended March 31, 2022, the Company recognized interest expense related to the stated interest described in Firstfire Note No. 1 and Firstfire Note No. 2 (collectively, the “Firstfire Notes”) of $0 and $79,200, respectively. During the three and nine months ended March 31, 2022, the Company recognized interest expense related to the 25% default penalty and 1% liquidated damages of $191,400. In addition, the Company recognized the accretion of the debt discount on the Firstfire Notes during the three and nine months ended March 31, 2022 of $0 and $660,000, respectively.

As of March 31, 20152022, the Firstfire Note No. 1 and June 30, 2014,No. 2 are convertible into 39,198,000 shares of common stock.

Geneva Promissory Note dated April 26, 2021

On April 26, 2021, the Company had 26,172,000 and 23,400,000Geneva Roth Remark Holdings, Inc. ("Geneva") entered into a Securities Purchase Agreement (the "SPA"). Pursuant to the SPA, The Company sold to Geneva a Promissory Note for the principal amount of $86,625 (the "Geneva Promissory Note ") and issued a warrant to purchase up to 51,975 shares of common stock issued(the “Geneva Warrant”). Under the Geneva Promissory Note the Company received net proceeds of $75,000 which included deductions for a 10% original issue discount, $3,000 for legal fees and outstanding, respectively.$750 as a due diligence fee. The Geneva Promissory Note matured in one (1) year, requires ten (10) monthly payments of $9,529 beginning June 1, 2021, and is unsecured. On August 9, 2021, the Company repaid, in whole, the balance due under the Geneva Promissory Note, or $57,173.

 

On January 15, 2014 the Company sold 400,000 shares of common stock for $400.


15

During the nine months ended March 31 2015,2022, the Company made payments totaling $76,230 including principal of $70,780 and interest of $5,450, and recognized accretion of the debt discount of $27,460.

Geneva Convertible Promissory Notes dated July 13, 2020, August 3, 2020 and September 8, 2020

On July 13, 2020, August 3, 2020 and September 8, 2020 (the “Issue Dates”), the Company and Geneva entered into separate and identical Securities Purchase Agreements (the "Geneva SPAs"). Pursuant to the Geneva SPAs, Geneva and the Company entered into separate and identical Convertible Promissory Notes also dated as part of a private placement,July 13, 2020, August 3, 2020 and September 8, 2020 for principal amounts of $63,000, $55,000 and $53,000, respectively (the "Geneva CPNs"). Pursuant to the terms of the Geneva CPNs, the Company received net proceeds of $119,200 for the sale$60,000, $52,000 and $50,000 (the proceeds from each note were funded net of 1,192,000 shares$3,000 in legal fees). The Geneva CPNs matured in one year, accrued interest of common stock at a price of $0.10 per share.  


On February 6, 2015 the Company agreed to convert the principal outstanding balance of five promissory notes10% and, after 180 days, were convertible into shares of common stock any time at a rate of $0.10 per share.  As partconversion price equal to 58% of the lowest trading price during the twenty-trading day period ending on the latest complete trading day prior to the conversion date. The Geneva CPN’s may be prepaid anytime up to 180 days from issuance with the following prepayment penalties: 1) The period beginning on the Issue Date and ending on the date which is ninety (90) days following the Issue Date, 125%; 2) The period beginning on the date that is ninety-one (91) day from the Issue Date and ending one hundred fifty (150) days following the Issue Date, 135%; and 3) The period beginning on the date that is one hundred fifty-one (151) day from the Issue Date and ending one hundred eighty (180) days following the Issue Date, 139%.

On December 21, 2020, the Company paid $90,487 as full payment of the Geneva CPN dated July 13, 2020. The payment included $63,000 of principal, $2,917 of interest related to the coupon and $24,570 as a prepayment penalty recorded as interest expense.

On February 16, 2021, Empire Associates, Inc., an unaffiliated company, paid off the balance, in-full, on the note holdersdated August 3, 2020. The payment totaled $77,061 and included $55,000 of principal, $3,256 of interest related to the coupon and $18,805 as a prepayment penalty recorded as interest expense. At the time of payoff, the Company and Empire Associates, Inc. had not entered into any agreements related to the payment of the Geneva CPN dated August 3, 2020. On April 20 the Company and Empire Associates, Inc. entered into a Stock Purchase Agreement whereby the Company agreed to forgo any interest payments due.  Theissue 250,000 to Empire Associates, Inc. in full satisfaction of the $77,061 paid to Geneva on behalf of the Company.

On March 15, 2021, the Company issued 1,380,000146,486 shares of common stock forto Geneva upon their conversion, in-full, of $53,000 of Principal and $2,650 of unpaid interest owing under the extinguishmentGeneva CPN dated September 8, 2020.

The debt discount attributable to the legal fees paid and fair value of notes payablethe beneficial conversion feature contained in the amountGeneva CPNs amounted to $132,831 and was accreted over the term of $138,000.the Geneva CPNs. In the event a Geneva CPN was paid in advance of its maturity date, the future accretion was recorded in the period the related Geneva CPN was repaid.

The Geneva CPNs were repaid in full in fiscal 2021. During the three and six months ended December 31 2020, the Company recognized $4,604 and $7,173 of interest expense, and $59,326 and $79,149, respectively, of accretion related to the debt discount.

NOTE 6 - Leases

On September 14, 2021, the Company leased 6,900 square feet of office and light industrial space located at 1130 Calle Cordillera, San Clemente, California and entered into a Standard Multi-Tenant Office Lease (the “Lease”). Pursuant to the Lease the term is five years beginning on October 15, 2021, the Company paid a security deposit of $32,621, and monthly base rent is $9,696 subject to an annual increase of 3% each year.

As of March 31, 2022, the Company has not entered into any leases other than the lease described above which have not yet commenced and would entitle the Company to significant rights or create additional obligations.

The components of lease expenses are as follows:

16

  Three Months Ended March 31,
  2022 2021
Operating lease cost $30,887  $—   

Supplemental balance sheet information related to the Lease is as follows:

  March 31, 2022
   
Operating lease right-of-use asset $476,125 
     
Current maturities of operating lease $88,347 
Non-current operating lease  391,375 
     Total operating lease liabilities $479,722 
     
Weighted Average remaining lease term (in years):  4.54 
Discount rate:  6.76%

The Company’s future lease payments, which are presented as current maturities of operating leases and non-current operating lease liabilities on the Company’s balance sheets as of March 31, 2022 are as follows:

  Amount
2022 remaining$29,089
2023 118,975
2024 122,544
2025 126,220
2026 130,007
2027 32,740
     Total lease payments 559,575
Less: Imputed interest (79,853)
     Total lease obligation 479,722
Less: current lease obligations 88,347
     Long term lease obligations$391,375


NOTE 7 – Commitments and Contingencies

 

NOTE 8 – COMMITMENTS AND CONTINGENCIESOn September 14, 2021, the Company leased 6,900 square feet of office and light industrial space located at 1130 Calle Cordillera, San Clemente, California. See “Note 6 - Leases” for additional information.

 

Leases Obligations

AsOn February 17, 2022, the Securities and Exchange Commission filed a lawsuit in the federal district court for the Southern District of March 31, 2015,California, charging the Company, doesformer CEO Charles Strongo, and four stock promoters with violations of section 10(b) of the Securities Exchange Act of 1934 and section 17(a) of the Securities Act of 1933.  The SEC’s complaint seeks injunctive relief, disgorgement of funds allegedly received from illegal conduct plus pre-judgment interest, and the civil penalties. On the same day, the US Attorney’s Office for the Southern District of California announced the unsealing of an indictment charging Mr. Strongo and the promoters with conspiring to manipulate the market for the Company’s in an alleged “pump-and-dump” scheme through allegedly false and misleading statements in press releases and SEC filings concerning the Company’s emergency use authorization submissions to the Food and Drug Administration for COVID-19 tests.  Mr. Strongo adamantly denies the allegations and has entered a plea of not lease space for offices or operations.


Consulting Agreement

In March 2013,guilty to the charges. Due to the nature and early stage of the SEC Action, the Company entered into one year investor relation service agreement which expires March 2014, foris unable to estimate the annual flat rate of $55,000. The service agreement was renewed and expires March 1, 2015.  Duringtotal costs to defend itself or the six months ended March 31, 2014potential costs to the Company recognized $27,500 in expense related to this agreement and has included $26,258 and $33,758the event that it is not successful in accrued liabilities as of March 31, 2014 and June 30, 2014, respectively.its defense.


On July 1, 2014, the Company entered into one year investor relation service agreement which expires June 30. 2015, for the annual flat rate of $25,000.  During the nine months ended March 31, 2015, the Company recognized $12,500 in expense related to this agreement and has included $1,100 and $0 in accrued liabilities as of March 31, 2015 and June 30, 2014, respectively.

 

NOTE 98SUBSEQUENT EVENTS



On April 1, 2015, the Company transferred the right/interest in the oil & gas well to Axiom Group for the release the debts owed to Axiom Group.


Subsequent Events

 

Management has reviewed material events subsequent of the period ended March 31, 2022 and prior to the filing of our consolidated financial statements in accordance with FASB ASC 855 “Subsequent Events”.


17


ItemItem 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Texas Jack Oil & Gas

Forward-Looking Statements

This Report on Form 10-Q contains forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, and are generally identifiable by use of words such as “may” “will” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project,” or the negative of these words or other variations on these words or comparable terminology. These statements are expressed in good faith and based upon a reasonable basis when made, but there can be no assurance that these expectations will be achieved or accomplished.

Such forward-looking statements include statements regarding, among other things, (a) the potential markets for our products, our potential profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in the in-vitro diagnostics industry, (d) our future financing plans, and (e) our anticipated needs for working capital. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in this Form 10-Q generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading.

Although forward-looking statements in this report reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, other than as may be required by applicable law or regulation. Readers are urged to carefully review and consider the various disclosures made by us in our filings with the Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect our actual results may vary materially from those expected or projected.

Except where the context otherwise requires and for purposes of this Form 10-Q only, “we” “us“ “our“ “Company“ “our Company“ and “Global WholeHealth Partners” refer to Global WholeHealth Partners Corporation, is referred to hereinafter as “we”, “our”, or “us”.a Nevada corporation.


OverviewOur Business


We have limited revenuessell products internationally which are not FDA approved to sell in the US. These products include an FDA Certificate of Exportability and operating history. Our independent auditor has issuedinclude tests such as Ebola, ZIKA, Dengue, Malaria, Influenza, Tuberculosis, Corona Viruses, and other vector borne diseases.

As a result of the COVID-19 pandemic, the Company became laser focused on developing and selling COVID tests beginning in the second half of fiscal 2020. The Company achieved sales of COVID tests in fiscal 2021 that were sourced from third parties. In addition, over the course of fiscal 2021, the Company continued its efforts to develop an audit opinionRDT, RT-PCR and antigen test. Due to the relatively quick commoditization of COVID-19 tests, the Company’s strategy of selling third party tests until it could complete a COVID test of its own proved ill-timed and caused a drop in sales in the latter part of fiscal 2021. As a result, the Company refocused its attention on marketing its core FDA OTC approved products which includes tests for pregnancy, ovulation, colorectal, drugs of abuse, glucose strips and glucose monitors through various platforms, including Walmart, Amazon and eBay, in addition to the development of a statement expressing substantial doubtCOVID antigen test being developed under a Memorandum of Understanding (“MOU”) dated September 15, 2021 between Global WholeHealth Partners, Avant Gen, Inc. and Pan Probe Biotech. Pursuant to the MOU, the parties thereto have developed a rapid Covid-19 antigen test. The work under the MOU has resulted in the filing of clinical studies with the NIH and we are hoping to receive an FDA EUA approval in fiscal Q3. In addition, the Company has developed a saliva based rapid COVID-19 test not subject to the MOU which the company plans to file with the NIH seeking an FDA EUA which the Company hopes to receive in fiscal Q4.

18

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs to allow it to continue as to oura going concern.

The ability of the Company to continue as a going concern as filed in our June 30, 2014 10-K filedis dependent on September 30, 2014. We usedthe Company obtaining adequate capital to own a 3% working interest in one wellfund operating losses until it becomes profitable. If the Bright 1H, which was drilled in late summer of 2012 and was completed and placed into production in October 2012. On April 1, 2015, we transferred this right/interestCompany is unable to Axiom Group for the release the debts owedobtain adequate capital, it could be forced to Axiom Group.


Uncertainties and Trendscease operations.

 

Our revenues are dependent in the future, upon the following factors:


·

price volatility in worldwide oil prices, which is affected by: (a) interest rates; (b)currency exchange rates (c) inflation or deflation; (d) speculation and (e) production levels;

·

global and regional supply and demand for oil;

·

political and economic conditions;

·

changes in the regulatory environment, which may lead to increased costsAs of doing business;

·

our ability to raise adequate working capital;

·

success of our development and exploration;

·

level of our competition;

·

our ability to attract and maintain key management and employees; and

·

our ability to efficiently explore, develop and produce sufficient quantities of marketable natural gas or oil in a highly competitive and speculative environment while maintaining quality and controlling costs.


The following discussion and analysis should be read in conjunction with our Financial Statements and notes thereto.

Results of Operations for the Three Months Ended March 31, 2015 as Compared to the Three Months Ended March 31, 2014


The following sets forth certain information regarding our results2022, we had negative working capital of operations$1,671,290, a cash balance of $27,416 and inventory balance of $86,000. Management recognizes that in order for the three months ended March 31, 2014 and 2013:

Three Months Ended March 31

 

2015

 

 

2014

 

Revenue

 

$

-

 

 

$

386

 

Selling, general and administrative expenses

 

 

(1,770

 

 

(5,331

)

Net operating loss

 

 

(1,770

 

 

(5,331

Other income (expense)

 

 

0

 

 

 

1,993

 

Net loss

 

 

(1,770

)

 

 

(4.945

)

Net loss per share - basic and diluted

 

 

(0.00

 

 

(0.00

)

Weighted average shares - basic and diluted

 

 

25,408,739

 

 

 

23,324,444

 

Our operations have resulted in significant losses and negative cash flow as we have invested in our property lease interests.

Revenue


For the three months ended March 31, 2015 our revenue was $0 as compared to $386 for the three months ended March 31, 2014.  The decrease in revenue is due to the well in Jack County, TX changing operators.  




Selling, general and administrative expenses


For the three months ended March 31, 2015 our selling, general and administrative costs were $1,770 as compared to $5,331 for the three months ended March 31, 2014.  The decrease in selling, general and administrative expenses was primarily due to a decrease in professional fees, officer compensation and travel related expenses.

Other expense


For the three months ended March 31, 2015 our other expenses were $0 as compared to $1,993 for the three months ended March 31, 2014.  The decrease in our other expenses was due to a decrease in interest expense attributable to an increase on borrowed debt.


Net loss


For the three months ended March 31, 2015 our net loss was $1,770 as compared to $4,945 for the three months ended March 31, 2014.


Results of Operations for the Nine Months Ended March 31, 2015 as Compared to the Nine Months Ended March 31, 2014


The following sets forth certain information regarding our results of operations for the nine months ended March 31, 2015 and 2014:

Nine Months Ended March 31

 

2015

 

 

2014

 

Revenue

 

$

-

 

 

$

4,083

 

Selling, general and administrative expenses

 

 

(171,115

 

 

(39,629

)

Net operating loss

 

 

(171,115

 

 

(39,629

Other income (expense)

 

 

(5,045

 

 

(6,039

)

Net loss

 

 

(176,160

)

 

 

(41,585

)

Net loss per share - basic and diluted

 

 

(0.01

 

 

(0.00

)

Weighted average shares - basic and diluted

 

 

24,152,087

 

 

 

23,106,569

 

Our operations have resulted in significant losses and negative cash flow as we have invested in our property lease interests.

Revenue


For the nine months ended March 31, 2015 our revenue was $0 as compared to $4,083 for the nine months ended March 31, 2014.  The decrease in revenue is due to the well in Jack County, TX changing operators.  

Selling, general and administrative expenses


For the nine months ended March 31, 2015 our selling, general and administrative costs were $171,115 as compared to $39,629 for the nine months ended March 31, 2014.  The increase in selling, general and administrative expenses was primarily due to an increase in professional fees, officer compensation and travel related expenses.


Other expense


For the nine months ended March 31, 2015 our other expenses were $5,045 as compared to $6,039 for the nine months ended March 31, 2014.  The decrease in our other expenses was due to a decrease in interest expense attributable to an increase on borrowed debt.






Net Loss

For the nine months ended March 31, 2015 our net loss was $176,160 as compared to $41,585 for the nine months ended March 31, 2014.

Since inception we have generated $4,083 in revenues, therefore our general, administrative and other costs have exceeded the resources we have generated through operations. As described above in “Liquidity and Capital Resources,” we have been dependent on debt/equity financing,us to meet our working capital obligationsrequirements, and continue to operate, additional financing will be necessary. We expect to raise additional funds through private or public equity investment in order to expand the range and scope of our business operations. We will seek access to private or public equity but there is no assurance that such additional funds will be available for us to finance our continuing operating losses. Our current lack of production further complicates our abilityoperations on acceptable terms, if at all. If we are unable to raise additional capital or generate positive cash from these sources. There can be no assuranceflow, it is unlikely that we will be able to continue to finance our operating losses in suchas a manner. We have, however, been able to raise additional funds ingoing concern. The financial statements do not include any adjustments that might result from the past and we believe that we will be able to do so in the future.


Liquidity and Capital Resourcesoutcome of this uncertainty.

 

Continuing working capital deficitResults of Operations

 

Our working capital deficit has limited our ability to expand our operationsThree and pursue our business plan. The following table sets forth our continuing working capital (deficit) atnine months ended March 31, 20152022 compared with the three and June 30, 2014:

 

 

March 31, 2015

 

 

June 30, 2014

 

Current Assets

 

$

15

 

 

$

5,874

 

Current Liabilities

 

 

57,904

 

 

 

115,217

 

 

 

 

 

 

 

 

 

 

Working Capital (Deficit)

 

$

(57,889

)

 

$

(109,343


Our cash decreased by $5,859 from $5,874 as of June 30, 2014 to $15 atnine months ended March 31, 2015.2021

 

Our working capital deficit decreased by $51,454 to a $ 57,889 asRevenue and Cost of Revenue

During the three months ended March 31, 2015, from $109,343 at June 30, 2014.  Accounts payable2022 and accrued expenses increased from $36,384 as2021, the Company’s sales totaled $7,000 and $2,460, respectively with cost of June 30, 2014 to $48,238 assales of March 31, 2015.

Our notes payable decreased by $72,000 to $ 0 as of March 31, 2015, from $72,000 at June 30, 2014.


$33,681 and $54,540, respectively. During the nine months ended March 31, 2015,2022 and 2021, the Company’s sales totaled $7,375 and $39,920, respectively.

During the three months ended March 31, 2022 and 2021, the Company’s cost of revenue totaled $33,681 and $54,540. During the nine months ended March 31, 2022 and 2021, the Company’s cost of revenue totaled $33,681 and $82,671, respectively. The elevated cost of revenue was due to the fair value adjustment to inventory for the shelf-life expiration of some products which totaled $29,681 and $51,615 during the three and nine months ended March 31, 2022 and 2021, respectively, resulting in negative gross profit.

Operating Expenses

    

Three Months Ended March 31,

 Increase /
    2022 2021 (Decrease)
Operating expenses:          
   Professional fees   $32,132  $14,400  $17,732
   Research and development    3,000   30,000  (27,000)
   Selling, general and administrative    142,560   22,980  119,580
   Stock compensation    728,950   2,544,000  (1,815,050)
Total operating expenses   $906,642  $2,611,380  $(1,704,738)

19

    Nine Months Ended March 31, Increase /
    2022 2021 (Decrease)
Operating expenses:          
   Professional fees   $103,532  $61,625  $41,907
   Research and development    1,372,697   234,010  1,138,687
   Selling, general and administrative    805,822   77,641  728,181
   Stock compensation    1,709,550   2,544,000  (834,450)
Total operating expenses   $3,991,601  $2,917,276  $1,074,325

Professional Fees

Professional fees relate to expenditures incurred primarily for legal and accounting services. During the three and nine months ended March 31, 2022 compared to the three and nine months ended March 31, 2021 professional fees increased primarily due to increased fees for accounting and legal services.

Research and Product Development

Research and Product Development (“R&D”) costs represent costs incurred to develop our tests and are incurred pursuant to certain internal R&D cost allocations, when applicable, and agreements with third-party providers, but primarily with Pan Probe Biotech, owned by Dr. Shujie Cui, our Chief Science Officer. R&D costs are expensed when incurred. During the three and nine months ended March 31, 2022 compared to the three and nine months ended March 31, 2021, R&D costs increased due to the development of a COVID antigen test. The timing of the development costs is not expected to be consistent from period to period.

Selling, General and Administrative

Selling, general and administrative (“SG&A”) costs include all expenditures related to personnel, rent, travel, public company costs, utilities, marketing and other office related costs. SG&A costs increased during the three and nine months ended March 31, 2022 over the prior year primarily due increases in personnel costs, marketing costs, rent other administrative costs.

Stock Compensation

Stock compensation represents the expense associated with the issuance of stock in exchange for services and is non-cash in nature. Stock compensation is based on our stock price at the measurement date and fluctuates as our stock price changes. During the three months ended March 31, 2022, the Company issued 12,500,000 shares of common stock valued at $688,000 and recognized $32,250 of deferred stock compensation and $8,700 for unissued shares. During the nine months ended March 31, 2022, the Company issued 16,000,000 shares of common stock valued at $1,733,000 and recognized $96,750 of deferred stock compensation and $8,700 for unissued shares with $32,250 to be recognized over the final fiscal quarter of 2022.

Other Income and (Expense)

Other expense includes “interest expense” which relates to the stated interest and penalties upon default of our outstanding promissory notes, and “amortization of debt discount” which represents the accretion of the discount applied to our notes as a result of the issuance of detachable warrants and the beneficial conversion feature contained certain notes. During the three months ended March 31, 2022, interest expense totaled $690. During the nine months ended March 31, 2022, interest expense totaled $279,697 and included $191,400 of liquidated damages and penalties due to our default on the Firstfire Notes and $79,200 of interest expense related to the Firstfire Notes.

Liquidity and Capital Resources

As of March 31, 2022, our cash totaled $27,416, compared to current liabilities of $1,895,932. From inception to March 31, 2022, we have incurred an accumulated deficit of $18,767,796. This loss has been incurred through a combination of professional fees, R&D, SG&A and non-cash stock related costs of $13,203,119 to support our plans to develop our business. During the three and nine months ended March 31, 2022, the Company had negligible revenues and used cash in operations of $1,940,791. The Company has incurred losses since inception and may not be able to generate sufficient net revenue from its business in the future to achieve or sustain profitability. The Company currently has insufficient funds to operate over the next twelve months. To finance our operations, we have entered into a Common Stock Purchase Agreement with EMC2 Capital LLC, which provided us with $76,871 and $1,476,872 during the three and nine months ended March 31, 2022, respectively. Additionally, we entered into a Securities Purchase Agreement and related 12% senior secured convertible promissory note on June 18, 2021 and August 27, 2021, under which the Company received net proceeds of $224,500 on July 8, 2021 and $313,700 on September 2, 2021. We are currently pursuing additional funds through equity or debt financing or a combination thereof. However, aside from the EMC2 SPA, the Company has no commitments to obtain any such financing, and there can be no assurance that financing will be available in amounts or on terms acceptable to the Company, if at all.

20

Summary of Cash Flows

Presented below is a table that summarizes the cash provided or used in our activities and the amount of the respective increases or decreases in cash provided by (used in) those activities between the fiscal periods:

  Nine Months Ended March 31, Increase / (Decrease)
  2022 2021  
Operating activities $(1,940,791) $(496,861) $1,443,930 
Investing activities  —     (3,505)  (3,505)
Financing activities  1,893,505   486,698   (1,406,807)
Net increase (decrease) in cash $(47,286) $(13,668) $33,618 

Operating Activities

Net cash used in operating activities totaled $ 120,059.Cash provided by financingincreased $1,443,930 primarily due to increases in R&D, professional fees, personnel and other SG&A costs.

Investing Activities

Net cash used in investing activities decreased $3,505 due to the purchase of computer equipment during the nine months ended March 31, 2015 was $114,200 and is attributable2021 compared to $119,200no investing related cash flows during the nine months ended March 31, 2022.

Financing Activities

During the nine months ended March 31, 2022, the Company received in proceeds from$1,479,000 upon the issuancesale of 7,856,514 shares of common stock, in a private placement,and $538,200 from the sale of convertible promissory notes offset against $5,000 inby debt payments on notes payable.

We continue to focus on conserving cash, setting priorities for our most important obligations and seeking other means to pay or defer any obligations as necessary.totaling $123,565.

 

In July 2014, the Company began offering for sales shares of its $0.001 par value common stock at a price of $0.10 per share.  The maximum amount of this offering is $500,000.  The Company intends to use the proceeds of this financing for the lease of additional oil and gas properties, the acquisition of additional working interests, general and administrative expenses, legal and accounting costs, and working capital.Other Contractual Obligations

 

Property and equipmentNone.


We do not have any property and equipment as of March 31, 2015 and June 30, 2014.


Capital commitments


We do not have any long term debt, capital lease obligations, operating or purchase obligations at March 31, 2015.


Off-Balance Sheet Arrangements




13




We do not have any off-balance sheet arrangements that have or commitments thatare reasonably likely to have a current or future effect on itsour financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that isare material other than those which may be disclosed in this Management’s Discussionto investors.

Critical Accounting Policies

Our discussion and Analysisanalysis of Financial Conditionour financial condition and the unauditedresults of operations are based upon our Financial Statements, and related notes.

Critical Accounting Policies


which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of unaudited condensedthese financial statements in conformity with generally accepted accounting principles requires our managementus to make estimates and assumptionsjudgments that affect the reported amountamounts of assets, liabilities, revenues, and liabilitiesexpenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on its historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities atthat are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

21

Due to the datelevel of activity and lack of complex transactions, we believe there are currently no critical accounting policies and estimates that affect the unaudited condensedpreparation of our financial statements.

Recently Issued Accounting Pronouncements

See Note 2 to our consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.


Going Concern


During the nine months ended March 31, 2015, we generated no revenue and we had an accumulated deficit of $3311,223. We will need significant financing to implement our business plan. Our unaudited condensed financial statements have been prepared assuming that we will continue as a going concern.“Interim Statement Presentation - Accounting Pronouncements” under Item 1 in this Quarterly Report on Form 10-Q.

 

The accompanying unaudited condensed financial statements do not include any adjustmentsRelated Party Transactions

For a discussion of our Related Party Transactions, see “Note 4 - Transactions With Related Persons” to reflect the possible future effectsour Financial Statements included under Item 1 in this Quarterly Report on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.Form 10-Q.

 

Item 4. CONTROLS AND PROCEDURESControls and Procedures


Evaluation of Disclosure Controls and Procedures


We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended March 31, 2015 we carried out an evaluation, underUnder the supervision and with the participation of our management, including the principal executive officerour Chief Executive Officer and the principal financial officer (principal financial officer),Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e)Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 Act.(the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on this evaluation, becauseour Chief Executive Officer and Chief Financial Officer concluded that as of the Company’s limited resources and limited number of employees, management concludedMarch 31, 2022, that our disclosure controls and procedures were ineffective as of March 31, 2015.


Limitations on Effectiveness of Controlseffective such that the information required to be disclosed in our SEC filings is recorded, processed, summarized and Procedures


Ourreported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relativeas appropriate to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.allow timely decisions regarding required disclosure.

 

Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate



14




because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.Internal Control over Financial Reporting

 

Internal Controls over Financial Reporting


During the quarter ended March 31, 2015, there have beenThere were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that haveoccurred during the period covered by this report that has materially affected, or areis reasonably likely to materially affect, our internal controlscontrol over financial reporting.

 

22

PART II - OTHER INFORMATION


Item 1. Legal Proceedings


From time to time, we may becomeare involved in various lawsuitslitigation and other proceedings. See Note 7 to our unaudited consolidated financial statements for information on certain legal proceedings, which arise inis incorporated by reference herein.

Item 1A. Risk Factors

COVID-19 Pandemic Impact and Risk

Smaller reporting companies are not required to provide the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.information required by this Item 1A.


Item 2. RecentUnregistered Sales of UnregisteredEquity Securities and Use of Proceeds

 

None.


Item 3.  Defaults on Senior SecuritiesDuring the three months ended March 31, 2021, the Company issued 1) 12,500,000 shares in exchange for services valued at $688,000; 2) 2,666,666 shares upon the conversion of $80,000 of convertible note principal; and 3) 2,000,000 shares upon the exercise of a warrant.

 

None.All proceeds from sales of unregistered securities, if any, are used for general corporate purposes.


Item 4.  Mine Safety Disclosures

Not applicable.


Item 5.  Other Information

None.

23

 

Item 6. Exhibits


The following exhibits, required by Item 601 of Regulation S-K, are being filed as part of this quarterly report, or are incorporated by reference where indicated:

 

Exhibit NoDescription of Exhibit

Exhibit No.

2.1

Notice of Entry of Order, Eight Judicial District Court, Clark County, Nevada, Case No.: A-19-787038-P

Description(Incorporated by reference to the Form 10 filed on December 19, 2019)

3.1

Articles of Incorporation (Incorporated by reference to Form S-1 filed on January 28, 2014)

Exhibit 31.1

3.2
By-Laws (Incorporated by reference to Form S-1 filed on January 28, 2014)
3.3Certificate of Change dated May 9, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
3.4Certificate of Amendment dated May 9, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
3.5Certificate of Change dated August 30, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
4.1Stock Purchase and Sale Agreement between the Company and Lionsgate Funding Group, LLC dated May 23, 2019 (Incorporated by reference to Form 10 filed on December 19, 2019)
4.2Media and Marketing Services Agreement between Global WholeHealth Partners Corp and Empire Associates, Inc. dated August 18, 2020 (Incorporated by reference to the Form 8-K filed on August 21, 2020) 
4.3Form of Common Stock Purchase Agreement between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020) 
4.4Form of Common Stock Purchase Warrant between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020) 
4.5Registration Rights Agreement between Global WholeHealth Partners Corp and EMC2 Capital, LLC dated July 22, 2020 (Incorporated by reference to the Form 8-K filed on July 23, 2020)
4.6Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated July 13, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.7Form of Convertible Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated July 13, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.8Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated August 3, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.9Form of Convertible Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated August 3, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
4.10Form of Stock Purchase Agreement between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
4.11Form of Common Stock Purchase Warrant between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
4.12Form of Securities Purchase Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.13Form of Senior Secured Convertible Promissory Note between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.14Form of Security Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).

24

 

Exhibit No

Section 302 Description of Exhibit

4.15Form of Common Stock Purchase Warrant issued to by Global WholeHealth Partners Corp to Firstfire Global Opportunities Fund, LLC dated June 18, 2021. (Incorporated by reference to Form 10-K filed on September 27, 2021).
4.16Form of Securities Purchase Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.17Form of Senior Secured Convertible Promissory Note between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.18Form of Common Stock Purchase Warrant issued to by Global WholeHealth Partners Corp to Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
4.19Form of Registration Rights Agreement between Global WholeHealth Partners Corp and Firstfire Global Opportunities Fund, LLC dated August 27, 2021. (Incorporated by reference to Form 10-Q filed on November 5, 2021)
10.1Distribution Agreement and Letter of Exclusivity (Incorporated by reference to Form 10 filed on March 20, 2020)
10.2Form of Promissory Note between LionsGate Funding Group LLC and Global WholeHealth Partners Corp. dated March 29, 2020 (Incorporated by reference to the Form 10-Q filed on May 7, 2020)
10.3Form of convertible promissory Note dated April 18, 2020 (Incorporated by reference to the Form 10-K filed on September 28, 2020)
10.4Licensing Agreement with Charles Strongo dated January 12, 2021 (Incorporated by reference to the Form 8-K filed on January 21, 2021)
10.5Loan Agreement and Promissory Note between LionsGate Funding Group LLC and Global WholeHealth Partners Corp. dated January 27, 2021 (Incorporated by reference to the Form 10-Q filed February 16, 2021)
10.6License Agreement with Charles Strongo dated March 21, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
10.7Mutual Sales and Marketing Agreement dated April 12, 2021 (Incorporated by reference to the Form 8-K filed on April 19, 2021)
10.8Form of Promissory Note between Global WholeHealth Partners Corp and Geneva Roth Remark Holdings, Inc. dated April 26, 2021 (Incorporated by reference to Form 10-Q filed on May 24, 2021)
10.09Standard Multi-Tenant Office Lease-Net dated September 14, 2021 (Incorporated by reference to Form 10-Q filed on November 5, 2021)
10.10 Memorandum of Understanding dated September 15, 2021 between Global WholeHealth Partners, Avant Gen, Inc. and Pan Probe Biotech (Incorporated by reference to Form 8-K filed on September 21, 2021)
31.1Certification of Principal Executive Officer

and Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Exhibit 31.2

32.1

Section 302 Certification of Principal Financial/Accounting Officer

Exhibit 32.1

Section 906 Certification of Principal Executive Officer

Exhibit 32.2

and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 Certification of Principal Financial/Accounting Officer

101.INS

XBRL Instance Document

101.SCH

XBRL Schema Document

101.CAL

XBRL Calculation Linkbase

101.DEF

XBRL Definition Linkbase Document

101.LAB

XBRL Label Linkbase Document

101.PRE

XBRL Presentation Linkbase Document

the Sarbanes-Oxley Act of 2002*

 

SIGNATURES*Filed herewith

   

In accordance with

25

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned in the capacities and the dates indicated, thereunto duly authorized.


Global WholeHealth Partners Corp.

 

By: /S/ Rene Alvarez

Rene Alvarez

Chief Executive Officer, Chief Financial Officer and Director

(Principal Executive Officer and Principal Financial Officer)

Date: July 20, 2022

TEXAS JACK OIL & GAS CORPORATION

Date: May 20, 2015

By:

/s/ Seng Kok Wan

Name: Seng Kok Wan

Chief Executive Officer, President, Chief Financial Officer, and Secretary

(Principal Executive Officer and Principal Financial/Accounting Officer)

 

 

 




16



26